You are here
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
EVANSTON, Ill., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced a poster presentation at the Military Health System Research Symposium featuring results from preclinical studies of one of its three clinical-stage product candidates, NYX-783, a novel NMDA receptor modulator. The Food and Drug Administration has granted Fast Track designation to the development of NYX-783 as a therapy for post-traumatic stress disorder (PTSD).
“We are encouraged by the robust preclinical activity observed with NYX-783 in models of PTSD and traumatic brain injury and we look forward to advancing it further in clinical development,” said Joseph Moskal, Ph.D., chief scientific officer of Aptinyx. “We believe NYX-783 may represent a paradigm shift in the treatment of PTSD, addressing the underlying cause of the disorder rather than just the symptoms. We appreciate the opportunity to present these data at a forum that is uniquely focused on finding solutions to challenges that disproportionately affect military personnel.”
A Novel NMDA Receptor Modulator, NYX-783, Shows Therapeutic Potential as a Treatment for PTSD and TBI
Presenter: Luisa Cacheaux, Ph.D., and Katherine Leaderbrand, Ph.D., Aptinyx Inc.
Poster Presentation: Tuesday, August 21, 2018
Event: Military Health System Research Symposium, Gaylord Palms Resort & Convention Center, Kissimmee, FL
Summary: NYX-783 enhances learning and memory, as well as the ability to ameliorate affective and cognitive deficits in preclinical models of PTSD and traumatic brain injury (TBI).
NYX-783 has been evaluated in a Phase 1 clinical study and has demonstrated a favorable safety and tolerability profile in healthy volunteers. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Aptinyx’s development of NYX-783 for the treatment of PTSD.
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder (PTSD), and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our business plans and objectives, expectations regarding the design, implementation, enrollment, timing and success of our clinical trials and planned clinical trials, expectations regarding our preclinical development activities, and expectations regarding our uses of capital, expenses. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost and timing of our product candidate development activities and planned clinical trials; our ability to execute on our strategy; regulatory developments in the United States and foreign countries; our estimates regarding expenses, future revenue and capital requirements; as well as those risks and uncertainties set forth in our most recent quarterly report on Form 10-Q and in our other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
CONTACT: Investor Contact: Nick Smith Aptinyx Inc. email@example.com 847-871-0377 Media Contact: Jordann Phillips Canale Communications firstname.lastname@example.org 619-849-6009